Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Mônica Roberto GadelhaMarie BexRichard A FeeldersAnthony P HeaneyRichard J AuchusAleksandra Gilis-JanuszewskaPrzemyslaw WitekZhanna BelayaYerong YuZhihong LiaoChih Hao Chen KuDavide CarvalhoMichael RoughtonJudi WojnaAlberto M PedroncelliPeter J SnyderPublished in: The Journal of clinical endocrinology and metabolism (2022)
Osilodrostat rapidly normalized mUFC excretion in most patients with Cushing disease and maintained this effect throughout the study. The safety profile was favorable.